Options for Additional Medication for Diabetes After Metformin

First-Line Considerations

The American Diabetes Association recommends that metformin should be continued as the foundation of therapy when adding second agents, as long as it's tolerated and not contraindicated 1
For patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit should be added regardless of A1C level 2, 3
GLP-1 receptor agonists are preferred over insulin when possible due to their lower risk of hypoglycemia, favorable weight effects, and cardiovascular benefits 1, 2

SGLT2 inhibitors lower A1C by approximately 0.7-1.0% when added to metformin and provide cardiovascular and renal protection in high-risk patients 2, 4
GLP-1 receptor agonists reduce A1C by approximately 0.7-1.0% when added to metformin, offer cardiovascular benefits, weight reduction, and low hypoglycemia risk 2, 4
Sulfonylureas lower A1C by approximately 0.7-1.0% when added to metformin, are inexpensive and widely available, but have a higher risk of hypoglycemia compared to other options 4, 8, 9
Basal insulin is highly effective when hyperglycemia is severe (A1C >10% or blood glucose >300 mg/dL) and can be simplified or changed to oral agents as glucose toxicity resolves 5, 6, 9

For patients with established ASCVD, heart failure, or CKD, the first choice is an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit 2, 3, 6
For patients with obesity or where weight gain is a concern, the first choice is a GLP-1 receptor agonist or SGLT2 inhibitor 2, 9
For patients with high hypoglycemia risk, it is recommended to avoid sulfonylureas and insulin if possible and prefer SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors 2, 3, 9
For patients with severe hyperglycemia (A1C >10%), consider insulin therapy (with or without other agents) or GLP-1 receptor agonists 2, 5

Treatment intensification should not be delayed if glycemic targets are not met within approximately 3 months 1
Medication regimens should be reevaluated every 3-6 months and adjusted as needed 7
Initial combination therapy may be considered for patients with A1C levels 1.5-2.0% above target 6
Monitor for vitamin B12 deficiency with long-term metformin use, especially in patients with anemia or peripheral neuropathy 8